{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:16:25Z","timestamp":1783199785789,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14400-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:41:47Z","timestamp":1751337707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and efficacy of atezolizumab\/bevacizumab in unresectable hepatocellular carcinoma\u2014a multicentric study"],"prefix":"10.1186","volume":"25","author":[{"given":"Merin","family":"Babu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Sebastian","family":"Komaranchath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Valsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun R.","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"MP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley M.","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil K.","family":"Haridas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Soman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjima P.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shine","family":"Sadasivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Thabrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6129-5709","authenticated-orcid":false,"given":"Keechilat","family":"Pavithran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"3","key":"14400_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"14400_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.","journal-title":"Nat Rev Dis Prim"},{"key":"14400_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73 Suppl 1 Supp","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 Suppl 1 Suppl 1:4\u201313.","journal-title":"Hepatology"},{"key":"14400_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jceh.2019.09.007","volume":"10","author":"A Kumar","year":"2020","unstructured":"Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, et al. 2019 Update of Indian National Association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the Puri II recommendations. J Clin Exp Hepatol. 2020;10:43\u201380.","journal-title":"J Clin Exp Hepatol"},{"key":"14400_CR5","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4254\/wjh.v7.i12.1708","volume":"7","author":"S Ashtari","year":"2015","unstructured":"Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: prevention strategy and planning. World J Hepatol. 2015;7:1708\u201317.","journal-title":"World J Hepatol"},{"key":"14400_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","volume":"15 Suppl 4","author":"AP Venook","year":"2010","unstructured":"Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5\u201313.","journal-title":"Oncologist"},{"key":"14400_CR7","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/liv.15251","volume":"42","author":"C-H Zhang","year":"2022","unstructured":"Zhang C-H, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42:2029\u201341.","journal-title":"Liver Int"},{"key":"14400_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333.","journal-title":"Hepatology"},{"key":"14400_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4103\/crst.crst_277_23","volume":"6","author":"VK Muddu","year":"2023","unstructured":"Muddu VK, Bonda A. Hepatocellular carcinoma in India: time for a new focus. Cancer Res Stat Treat. 2023;6:449.","journal-title":"Cancer Res Stat Treat"},{"key":"14400_CR10","doi-asserted-by":"publisher","first-page":"101447","DOI":"10.1016\/j.jceh.2024.101447","volume":"14","author":"S Giri","year":"2024","unstructured":"Giri S, Singh A. Epidemiology of hepatocellular carcinoma in India \u2013 an updated review for 2024. J Clin Exp Hepatol. 2024;14:101447.","journal-title":"J Clin Exp Hepatol"},{"key":"14400_CR11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"14400_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"14400_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/ygh2.477","volume":"3","author":"AV Kulkarni","year":"2021","unstructured":"Kulkarni AV, Fatima S, Sharma M, Kumar P, Gupta R, Padaki NR, Reddy N. Lenvatinib for unresectable hepatocellular carcinoma: the first Indian experience. GastroHep.com. 2021;3:407\u20138.","journal-title":"GastroHep.com"},{"key":"14400_CR14","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"14400_CR15","doi-asserted-by":"publisher","first-page":"e2300215","DOI":"10.1200\/GO.23.00215","volume":"9","author":"A Ramaswamy","year":"2023","unstructured":"Ramaswamy A, Kulkarni A, John G, Rauthan A, Patil S, Duseja A, et al. Survival of trial-like and non\u2013trial-like patients with immunotherapy in advanced hepatocellular carcinoma in real world: a collaborative multicenter Indian study (IMHEP). JCO Glob Oncol. 2023;9:e2300215.","journal-title":"JCO Glob Oncol"},{"key":"14400_CR16","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jceh.2023.02.003","volume":"13","author":"AV Kulkarni","year":"2023","unstructured":"Kulkarni AV, Krishna V, Kumar K, Sharma M, Patodiya B, Khan A, et al. Safety and efficacy of atezolizumab-bevacizumab in real world: the first Indian experience. J Clin Exp Hepatol. 2023;13:618\u201323.","journal-title":"J Clin Exp Hepatol"},{"key":"14400_CR17","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.21873\/anticanres.16051","volume":"42","author":"S Takeda","year":"2022","unstructured":"Takeda S, Namisaki T, Tsuji Y, Fujimoto Y, Murata K, Enomoto M, et al. Initial experience with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: a real-world retrospective study. Anticancer Res. 2022;42:5465\u201373.","journal-title":"Anticancer Res"},{"key":"14400_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/hep.32468","volume":"76","author":"A D\u2019Alessio","year":"2022","unstructured":"D\u2019Alessio A, Fulgenzi CAM, Nishida N, Sch\u00f6nlein M, von Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatology. 2022;76:1000\u201312.","journal-title":"Hepatology"},{"key":"14400_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"14400_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"14400_CR21","doi-asserted-by":"publisher","first-page":"e052294","DOI":"10.1136\/bmjopen-2021-052294","volume":"12","author":"H Yu","year":"2022","unstructured":"Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open. 2022;12:e052294.","journal-title":"BMJ Open"},{"key":"14400_CR22","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1111\/liv.15405","volume":"42","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, D\u2019Alessio A, Fulgenzi CAM, Nishida N, Sch\u00f6nlein M, von Felden J, et al. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. Liver Int. 2022;42:2538\u201347.","journal-title":"Liver Int"},{"key":"14400_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.21873\/invivo.13099","volume":"37","author":"YC Lee","year":"2023","unstructured":"Lee YC, Huang WT, Lee MY, Tsao CJ, Feng YH. Bevacizumab and atezolizumab for unresectable hepatocellular carcinoma: real-world data in Taiwan-Tainan Medical Oncology Group H01 trial. In Vivo. 2023;37:454\u201360.","journal-title":"In Vivo"},{"key":"14400_CR24","first-page":"238","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng A-L, et al. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2023;12:238\u201350.","journal-title":"Ther Adv Med Oncol"},{"key":"14400_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.21037\/hbsn-22-432","volume":"11","author":"S Itoh","year":"2022","unstructured":"Itoh S, Ikeda M. Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2022;11:876\u20138.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"14400_CR26","doi-asserted-by":"publisher","first-page":"175883592211485","DOI":"10.1177\/17588359221148541","volume":"15","author":"J Cheon","year":"2023","unstructured":"Cheon J, Kim H, Kim HS, Kim CG, Kim I, Kang B, et al. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2023;15:17588359221148540.","journal-title":"Ther Adv Med Oncol"},{"key":"14400_CR27","doi-asserted-by":"publisher","first-page":"175883592210802","DOI":"10.1177\/17588359221080298","volume":"14","author":"T de Castro","year":"2022","unstructured":"de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022;14:17588359221080298.","journal-title":"Ther Adv Med Oncol"},{"key":"14400_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s12072-022-10392-x","volume":"16","author":"CT Chen","year":"2022","unstructured":"Chen CT, Feng YH, Yen CJ, Chen SC, Lin YT, Lu LC, et al. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatol Int. 2022;16:1199\u2013207.","journal-title":"Hepatol Int"},{"key":"14400_CR29","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.3390\/cancers14071722","volume":"14","author":"V Himmelsbach","year":"2022","unstructured":"Himmelsbach V, Pinter M, Scheiner B, Venerito M, Sinner F, Zimpel C, et al. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers. Cancers (Basel). 2022;14:1722.","journal-title":"Cancers (Basel)"},{"key":"14400_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/hepr.13797","volume":"52","author":"T Tanaka","year":"2022","unstructured":"Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res. 2022;52:773\u201383.","journal-title":"Hepatol Res"},{"key":"14400_CR31","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol."},{"key":"14400_CR32","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.3390\/cancers15235532","volume":"15","author":"AG Singal","year":"2023","unstructured":"Singal AG, \u00d6zg\u00fcrdal K, Fan X, Vassilev Z, Pan X, Multani JK, et al. Real-world systemic treatment patterns after atezolizumab and bevacizumab in patients with hepatocellular carcinoma in the United States. Cancers (Basel). 2023;15:5532.","journal-title":"Cancers (Basel)"},{"key":"14400_CR33","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. Epub 2018 Apr 10. Erratum in: J Hepatol. 2018;69(5):1207. https:\/\/doi.org\/10.1016\/j.jhep.2018.08.009. PMID: 29653741.","DOI":"10.1016\/j.jhep.2018.08.009"},{"key":"14400_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5582\/bst.2021.01173","volume":"15","author":"G Qiu","year":"2021","unstructured":"Qiu G, Xie K, Jin Z, Jiang C, Liu H, Wan H, et al. The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus. Biosci Trends. 2021;15:148\u201354.","journal-title":"Biosci Trends"},{"key":"14400_CR35","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.3748\/wjg.v21.i12.3462","volume":"21","author":"M Quirk","year":"2015","unstructured":"Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462\u201371.","journal-title":"World J Gastroenterol"},{"key":"14400_CR36","doi-asserted-by":"crossref","unstructured":"Finn RS, Galle PR, Ducreux M, Cheng AL, Reilly N et al. Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and\/or Contralateral Portal Vein Invasion in IMbrave150. Liver Cancer. 2024;13(6):655-668.","DOI":"10.1159\/000539897"},{"key":"14400_CR37","doi-asserted-by":"crossref","unstructured":"Rodriguez-Russo C, Wu L, Bloom J, Cohen D, Buckstein M. Safety of Upfront Locoregional Therapy in Conjunction with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2022 22;114(3):e179.\u00a0","DOI":"10.1016\/j.ijrobp.2022.07.1072"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14400-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14400-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14400-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:41:48Z","timestamp":1751337708000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14400-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14400"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14400-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5863242\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee of Amrita School of Medicine (IEC-AIMS-2024-ONCO-177) on 13-08-2024 and was conducted as per principles of the Declaration of Helsinki and guidelines of the Indian Council of Medical Research. All the authors certify that they have obtained all appropriate patient consent for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and agreed to the published version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1026"}}